# AB Science clinical trials: 39 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 39 trials with AB Science as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by AB Science: 39 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ab-science

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 39
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 39, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 16, 2025 | NCT07174492 | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | AB Science | Phase 3 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 412 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07174492) |
| October 3, 2022 | NCT05564169 | Masitinib in Patients With Mild Alzheimer's Disease | AB Science | Phase 3 | Not yet recruiting | Alzheimer Disease | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05564169) |
| July 8, 2022 | NCT05449444 | Masitinib for the Treatment of Severe Mast Cell Activation Syndrome | AB Science | Phase 2 | Unknown | Mast Cell Activation Syndrome | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05449444) |
| July 1, 2022 | NCT05441488 | Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis | AB Science | Phase 3 | Suspended | Progressive Multiple Sclerosis | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05441488) |
| January 27, 2022 | NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | AB Science | Phase 1/2 | Recruiting | Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05211570) |
| January 20, 2022 | NCT05200169 | Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects | AB Science | Early phase 1 | Completed | Healthy Volunteers | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05200169) |
| September 17, 2021 | NCT05047783 | Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 | AB Science | Phase 2 | Unknown | Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019 | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05047783) |
| November 10, 2020 | NCT04622865 | Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 | AB Science | Phase 2 | Unknown | SARS-CoV 2, COVID-19, Coronavirus Disease 2019 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04622865) |
| April 3, 2020 | NCT04333108 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | AB Science | Phase 3 | Unknown | Indolent Systemic Mastocytosis | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04333108) |
| December 10, 2018 | NCT03771040 | Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels | AB Science | Phase 3 | Completed | Asthma | 347 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03771040) |
| December 6, 2018 | NCT03766295 | Masitinib Plus Gemcitabine in Pancreatic Cancer | AB Science | Phase 3 | Completed | Locally Advanced or Metastatic Pancreatic Cancer | 377 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03766295) |
| December 3, 2018 | NCT03761225 | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | AB Science | Phase 3 | Completed | Metastatic Castrate Resistant Prostate Cancer | 714 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03761225) |
| June 14, 2018 | NCT03556956 | Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer | AB Science | Phase 2/3 | Completed | Colorectal Cancer Metastatic | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03556956) |
| April 25, 2017 | NCT03127267 | Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | AB Science | Phase 3 | Recruiting | Amyotrophic Lateral Sclerosis | 495 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03127267) |
| November 16, 2015 | NCT02605044 | Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer | AB Science | Phase 3 | Terminated | Metastatic Colorectal Cancer | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02605044) |
| October 28, 2015 | NCT02588677 | Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) | AB Science | Phase 2/3 | Completed | Amyotrophic Lateral Sclerosis (ALS) | 394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02588677) |
| July 3, 2015 | NCT02490488 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | AB Science | Phase 2/3 | Completed | Ovarian Cancer | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02490488) |
| December 12, 2013 | NCT02009423 | Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence | AB Science | Phase 3 | Terminated | Gastro-Intestinal Stromal Tumour | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02009423) |
| June 7, 2013 | NCT01872598 | Masitinib in Patients With Mild to Moderate Alzheimer's Disease | AB Science | Phase 3 | Completed | Alzheimer Disease | 721 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01872598) |
| September 27, 2012 | NCT01694277 | Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib | AB Science | Phase 3 | Completed | Gastrointestinal Stromal Tumors | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01694277) |
| January 10, 2012 | NCT01506336 | Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib | AB Science | Phase 2 | Completed | Gastro Intestinal Stromal Tumor | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01506336) |
| November 11, 2011 | NCT01470131 | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | AB Science | Phase 3 | Terminated | Multiple Myeloma | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01470131) |
| October 12, 2011 | NCT01450488 | Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis | AB Science | Phase 2 | Completed | Multiple Sclerosis | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01450488) |
| October 10, 2011 | NCT01449162 | Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids | AB Science | Phase 3 | Completed | Asthma | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01449162) |
| September 14, 2011 | NCT01433497 | Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis | AB Science | Phase 3 | Completed | Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapse Free | 656 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01433497) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 14 |
| Phase 2/3 | 4 |
| Phase 3 | 19 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Terminated | 6 |
| Unknown | 4 |
| Recruiting | 2 |
| Not yet recruiting | 2 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Mastocytosis | 4 |
| Asthma | 3 |
| Arthritis, Rheumatoid | 3 |
| Multiple Sclerosis, Chronic Progressive | 3 |
| Alzheimer Disease | 3 |
| Amyotrophic Lateral Sclerosis | 3 |
| COVID-19 | 2 |
| Multiple Sclerosis | 2 |
| Mastocytosis, Systemic | 2 |
| Pruritus | 2 |
| Blushing | 2 |
| Piebaldism | 2 |
| Gastrointestinal Stromal Tumors | 2 |
| Neoplasm Metastasis | 2 |
| Multiple Myeloma | 2 |
| Recurrence | 2 |
| Pancreatic Neoplasms | 2 |
| Leukemia, Myeloid, Acute | 1 |
| GATA2 Deficiency | 1 |
| Mast Cell Activation Syndrome | 1 |
| Dementia | 1 |
| Cognition Disorders | 1 |
| Memory Disorders | 1 |
| Cerebrovascular Disorders | 1 |
| Ovarian Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B cleaning and waste management companies in the United States](https://specstream.ai/data/businesses/b2b-cleaning-and-waste-management-companies/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [Beach resorts in the United States](https://specstream.ai/data/businesses/beach-resorts/united-states)
- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
- [Car manufacturers in the United States](https://specstream.ai/data/businesses/car-manufacturers/united-states)
- [Pest control companies in the United States](https://specstream.ai/data/businesses/pest-control-companies/united-states)
